QuickLinks -- Click here to rapidly navigate through this document

Exhibit 10.25

EIGHTH AMENDMENT TO
MANUFACTURING & DISTRIBUTION AGEEMENT

        This EIGHTH AMENDMENT, dated as of August 27, 2002, amends that certain
Manufacturing & Distribution Agreement by and between GENSIA SICOR
PHARMACEUTICAL SALES, INC. ("Gensia Sicor") (assignee of Gensia Sicor
Pharmaceuticals, Inc., formerly Gensia Laboratories, Ltd.) and Baxter Healthcare
Corporation ("Baxter") (formerly Ohmeda Pharmaceutical Products Division Inc.)
dated as of February 27, 1996, as amended (the "Agreement").

        WHEREAS, Baxter has signed an Asset Purchase Agreement to acquire the
generic injectable human pharmaceutical business operated by Wyeth's ESI Lederle
division (the "Acquisition");

        WHEREAS, the proposed Acquisition is subject to review by the United
States Federal Trade Commission ("FTC") and other governmental authorities;

        WHEREAS, in the course of its review, the FTC has requested that Baxter
divest its exclusive distribution rights to Gensia Sicor's pancuronium,
metoclopramide and vecuronium;

        WHEREAS, Baxter will conclude the Acquisition shortly after all
regulatory approvals are obtained (the "Closing Date");

        NOW, THEREFORE, in consideration of the mutual promises contained in
this Amendment, and for good and other valuable consideration, the parties
hereto agree as follows:

        1.    Baxter's exclusive distribution rights for pancuronium,
metoclopramide and vecuronium will be terminated, effective as of the Closing
Date. Baxter shall notify Gensia Sicor of the Closing Date of the Acquisition.

        2.    Exhibit A is amended to delete pancuronium, metoclopramide and
vecuronium, effective as of the Closing Date of the Acquisition.

        3.    Gensia Sicor shall cooperate, in good faith, with the FTC in
relation to the termination of Baxter's distribution rights for pancuronium,
metoclopramide and vecuronium, and shall undertake such actions as are
reasonably required by the FTC in relation to the Acquisition.

        4.    Baxter shall use reasonable commercial efforts, to secure
approvals and effect assignments to Gensia Sicor, of Baxter's Group Purchasing
Organization contracts for pancuronium, metoclopramide and vecuronium then in
effect as of the Closing Date of the Acquisition. Notwithstanding, Gensia Sicor
shall use reasonable commercial efforts to make available and sell pancuronium,
metoclopramide and vecuronium after the Closing Date. The parties will agree in
good faith on reasonable transitional provisions with respect to assigned
contracts, including without limitation change of labeling and re-direction of
chargebacks, returns and other adjustments to sales. After the Closing Date and
until a contract is assigned, or in the event a contract cannot be assigned,
Gensia Sicor will supply products directly to wholesalers or other customers,
and Baxter will remit all payments to Gensia Sicor. Baxter agrees not to
interfere with contracts assignable to Gensia Sicor.

        5.    Except as specifically set forth above, all other terms and
conditions set forth in the Agreement shall remain unchanged.

        6.    This amendment will be void if Baxter does not receive the
required consents and approvals of governmental authorities and other third
parties, including approval of the FTC, as necessary, or does not close the
Acquisition.

--------------------------------------------------------------------------------

        IN WITNESS WHEREOF the parties hereto have executed this Amendment as of
the date first above written.

GENSIA SICOR PHARMACEUTICAL SALES, INC.   BAXTER HEALTHCARE CORPORATION
By:
 
/s/  MARVIN SAMSON      

--------------------------------------------------------------------------------

 
By:
 
/s/  RONALD QUADREL      

--------------------------------------------------------------------------------

Name:
 
Marvin Samson

--------------------------------------------------------------------------------

 
Name:
 
Ronald Quadrel

--------------------------------------------------------------------------------

Title:
 
Chairman and CEO

--------------------------------------------------------------------------------

 
Title:
 
Vice President & General Manager

--------------------------------------------------------------------------------

GENSIA SICOR PHARMACEUTICALS, INC.
 
 
 
 
By:
 
/s/  MARVIN SAMSON      

--------------------------------------------------------------------------------

 
 
 
 
Name:
 
Marvin Samson

--------------------------------------------------------------------------------

 
 
 
 
Title:
 
Chairman and CEO

--------------------------------------------------------------------------------

 
 
 
 

2

--------------------------------------------------------------------------------

QuickLinks

Exhibit 10.25

EIGHTH AMENDMENT TO MANUFACTURING & DISTRIBUTION AGEEMENT